docetaxel anhydrous has been researched along with Angioblastic Meningioma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, A; Aldape, K; An, S; Baran, A; Chandler, JP; David James, C; Heimberger, AB; Horbinski, C; Lukas, RV; Magill, ST; McCortney, K; O'Shea, K; Pokorny, JL; Sachdev, S; Sahm, F; Scholtens, D; Tran, AN; Unruh, D; Walshon, J; Wang, W; Wang, Y; Youngblood, MW; Zhang, L | 1 |
1 other study(ies) available for docetaxel anhydrous and Angioblastic Meningioma
| Article | Year |
|---|---|
Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas.
Topics: Animals; Antineoplastic Agents; DNA Methylation; Docetaxel; Meningeal Neoplasms; Meningioma; Mice | 2023 |